Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
1 - 20 . (canceled)
21 . A method of treating a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
22 . A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
23 . The method of claim 21 , wherein the first compound is an anti-inflammatory; and the second compound is associated with Tau or alpha-Synuclein.
24 . The method of claim 22 , wherein the first compound is an anti-inflammatory; and the second compound is associated with Tau or alpha-Synuclein.
25 . The method of claim 23 , wherein the anti-inflammatory compound is selected from the group consisting of cromolyn, a cromolyn derivative, a cromolyn analog, eugenol, nedocromil, pemirolast, olopataidne, alfatoxin G 1 alfatoxin B1, alfatoxin M 1 deoxynivalenol, zearalenone, ochratoxin A, fumonisin B 1 hydrolyzed fumonisin B 1 patulin, ergotamine,
26 . The method of claim 23 , wherein the anti-inflammatory compound is a non-steroidal anti-inflammatory drug (NSAID).
27 . The method of claim 26 , wherein the anti-inflammatory compound is selected from the group consisting of acetylsalicylic acid, diflunisal, salsalate, ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, nabumetone, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib, licofelone, hyperforin, and figwort.
28 . The method of claim 23 , wherein the second compound is an inhibitor of tau protein aggregation.
29 . The method of claim 28 , wherein the inhibitor of tau protein aggregation is methylthioninium chloride.
30 . The method of claim 24 , wherein the anti-inflammatory compound is selected from the group consisting of cromolyn, a cromolyn derivative, a cromolyn analog, eugenol, nedocromil, pemirolast, olopataidne, alfatoxin G 1 alfatoxin B1, alfatoxin M 1 deoxynivalenol, zearalenone, ochratoxin A, fumonisin B 1 hydrolyzed fumonisin B 1 patulin, ergotamine,
31 . The method of claim 24 , wherein the anti-inflammatory compound is a non-steroidal anti-inflammatory drug (NSAID).
32 . The method of claim 31 , wherein the anti-inflammatory compound is selected from the group consisting of acetylsalicylic acid, diflunisal, salsalate, ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin, loxoprofen, indomethacin, tolmetin, sulindac, etodolac, ketorolac, diclofenac, nabumetone, piroxicam, meloxicam, tenoxicam, droxicam, lornoxicam, isoxicam, mefenamic acid, meclofenamic acid, flufenamic acid, tolfenamic acid, celecoxib, licofelone, hyperforin, and figwort.
33 . The method of claim 24 , wherein the second compound is an inhibitor of tau protein aggregation.
34 . The method of claim 33 , wherein the inhibitor of tau protein aggregation is methylthioninium chloride.